This week in pharma highlights the hurdles shaping access: stalled UK drug pricing talks, EU approval for Madrigal’s Rezdiffra, and CVS’s coverage denial for Gilead’s HIV PrEP. For commercial and market access teams, these shifts underscore the need to anticipate payer decisions, adapt strategies, and balance innovation with affordability to drive both patient impact and business success.

Swiss pharma leaders face tariff risk, the FDA advances domestic manufacturing, and Insmed secures approval for Brensocatib, the first therapy for bronchiectasis. These developments highlight how trade, policy, and innovation are reshaping the biopharma landscape—and why commercial and market access teams must adapt quickly to anticipate disruption and capture opportunity.

Biotech is navigating capital scarcity, evolving deal structures, and scientific progress. EY’s Biotech Beyond Borders report underscores the reset, Sangamo advances Fabry gene therapy while seeking a partner, and the FDA expands options in EGFR-mutated lung cancer. For commercial leaders, success now means proving value early, forging smart alliances, and planning lean, adaptive launches.